市场调查报告书
商品编码
1102190
真实世界证据(RWE)解决方案全球市场~2029,按组件(数据集/服务),应用程序(市场准入,肿瘤学,神经病学,上市后),用户(製药/医疗保健提供商)Real-world Evidence (RWE) Solutions Market by Component (Datasets, Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2029 |
在预测期内,真实世界证据 (RWE) 解决方案的市场规模预计将以 11.8% 的复合年增长率增长,到 2029 年达到 49 亿美元。
医疗保健行业大数据的快速增长、从基于数量的护理向基于价值的护理转变、对个性化医疗的日益关注等因素是推动该市场增长的主要因素。此外,新兴市场、对端到端 RWE 服务的日益关注,以及可穿戴设备和人工智能在 RWE 中的日益普及,为进入者提供了巨大的增长机会。
本报告调查全球真实世界证据 (RWE) 解决方案市场,提供市场的定义和概述,分析市场增长的各种影响因素、法律和监管环境、市场规模的变化和预测、各种细分细分市场/地区/主要国家、竞争环境、主要公司概况等。
Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Forecast to 2029
The RWE solutions market is expected to grow at a CAGR of 11.8% from 2022 to 2029 to reach $4.9 billion by 2029
Following a thorough primary and secondary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, opportunities, and challenges.
Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to-end RWE services, and the rising adoption of wearable devices and AI in RWE.
The RWE solutions market is segmented by component (datasets and consulting services), application (market access & reimbursement/coverage decisions, drug development & approvals, post market surveillance, medical device development & approvals, and other applications), end user (pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users) and Geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyses their market shares at the global and regional levels.
Based on component, the datasets segment is expected to command the largest share of the global RWE solutions market in 2022 due to factors such as the rising dependence of outcome-based studies on real-world data, increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.
Based on application, the drug development & approvals segment is expected to witness the fastest growth rate during the forecast period. The increasing investments by pharma and biopharma companies in R&D, increasing demand for real-world data and real-world evidence for accelerating drug discovery and development, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE) are the factors contributing to the growth of this segment.
Based on end user, the pharmaceutical, biotechnology, & medical device companies segment is expected to witness the fastest growth rate during the forecast period. The increasing importance of RWE studies in drug development &approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings are the factors contributing to the growth of this segment.
An in-depth analysis of the geographical scenario of the RWE solutions market provides detailed qualitative and quantitative insights about the five major geographies (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to command the largest share of the global RWE solutions market in 2022, followed by Asia-Pacific and Europe. However, Asia-Pacific is slated to register the fastest growth rate. The growth of this regional market is driven by the growing demand for data defining the value and effectiveness of medicines, the increasing need for conducting real-world studies in drug R&D, and the rising government initiatives for promoting the use of real-world studies for regulatory decision-making.
Some of the key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
Global RWE Solutions Market, by Component
(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)
Global RWE Solutions Market, by Application
(Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)
Global RWE Solutions Market, by End User
(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)
Global RWE Solutions Market, by Geography